LYR-210 Depot for Adult Subjects with Chronic Sinusitis

This study is currently recruiting participants.

Primary Objective: This is a phase II, randomized, blinded, sham procedure-controlled, parallel-group trial to evaluate the efficacy, safety and tolerability of LYR-210 in adult subjects (ages 18+) with chronic sinusitis. LYR-210 is a combination product comprised of a drug depot, which contains the anti-inflammatory medication mometasone furoate (MF) pre-loaded in a single use applicator.

Principal Investigator: Campbell Baguley

Study Coordinator: Michelle Hennessy

Trial Website:

Last updated 25 November 2019.